Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Park, Eun Hye; Lee, Hyewon; Won, Young Joo; Ju, Hee Young; Oh, Chang‐Mo; Ingabire, Cecile; Kong, Hyun Joo; Park, Byung Kiu; Yoon, Ju Young; Eom, Hyeon Seok; Lee, Eun-Young; Park, Hyeon Jin

doi:10.5045/br.2015.50.4.204

Cited by 45 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, childhood AML remains a challenge because a significant portion of patients still succumb to death eventually. The overall incidence of childhood AML has been stable during recent decades worldwide [ 18 19 ]. However, the annual incidence of AML has decreased with a decrease in childhood population in this study ( Fig.…”

Section: Discussionmentioning

confidence: 99%

Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia

et al. 2018

View full text Add to dashboard Cite

BackgroundThe prognosis of pediatric acute myeloid leukemia (AML) has recently improved. This study aimed to describe the epidemiology, changes in treatment strategies, and improvement of outcomes in Gwangju-Chonnam children with AML over 2 decades.MethodsMedical records of 116 children with newly diagnosed AML were retrospectively reviewed for demographic characteristics, prognostic groups including cytogenetic risks, treatment protocols, and survival rates over the periods between 1996 and 2005 (Period I, N=53), and 2006 and 2015 (Period II, N=38).ResultsThe annual incidence of AML has decreased with reduced pediatric population. The 5-year Kaplan-Meier (K-M) estimated overall survival (OS) and event-free survival (EFS) rates in 110 AML patients were 53.2±5.1% and 43.8±5.1%, respectively. The 5-year OS rate significantly improved during period II (70.3±7.0%) as compared to that during period I (40.0±6.8%) (P =0.001). The 5-year OS was not significantly different among cytogenetic risk groups (P =0.11). Fifty-eight patients underwent hematopoietic stem cell transplantation (HSCT). The K-M 5-year estimated survival for transplanted patients was 53.7±7.0%, while that for chemotherapy-only patients was 30.1±9.1% (P =0.014). Among the prognostic factors, treatment modality was the only independent factor. The chemotherapy-only group had a relative risk of 2.06 for death compared with the transplantation group (P=0.015).ConclusionThe survival of Korean children with AML has improved to a level comparable with that of developed countries over 2 decades, owing to a change in induction strategy, better supportive care with economic growth, refinement of HSCT techniques including a better selection of patients based on prognostic groups, and stem cell donor selection.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The Korean data for the hematologic malignancies ( 12 ) and the myeloid malignancies ( 13 ) have been previously published. During 1999 to 2012, myeloid malignancies took 1.7% of all cancer incidences, and MPNs took 33.8% of the myeloid malignancies.…”

Section: Introductionmentioning

confidence: 99%

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea

2016

View full text Add to dashboard Cite

The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.

show abstract

“…The incidence of all cancers in Korea has doubled during the last 10 years, while that of acute myeloid leukemia (AML) has stagnated during the same period. As a result, the number of new cases of MM surpassed AML for the first time in 2012 by a narrow margin (1,272 for MM vs. 1,257 for AML) with an identical crude incidence rate (2.5/100,000 for both of them) [ 16 , 17 ]. Although the ASR of AML (2.0/100,000) was still higher than that of MM (1.6/100,000), probably resulting from the skewed distribution of AML toward the elderly population, we can actually regard MM as the second most common hematologic malignancy in Korea considering its recent higher trend of increase compared to AML [ 16 , 17 ].…”

Section: Global and Korean Epidemiologymentioning

confidence: 99%

Recent advances in multiple myeloma: a Korean perspective

Hong

Lee

2016

Korean J Intern Med

View full text Add to dashboard Cite

Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. Application of novel agents has resulted in significant improvement of treatment outcomes, and the advances are ongoing with the recent introduction and U.S. Food and Drug Administration’s approval of newer agents, including carfilzomib, ixazomib, elotuzumab, and daratumumab. In concert with the technical advances in the cytogenetic and molecular diagnostics of MM, modifications of its diagnosis and staging system have been attempted for better risk stratification. The modified diagnostic criteria from the International Myeloma Working Group in 2014 enabled a strategy of more active treatment for some patients with smoldering MM, with an ultra-high risk of progression, and fine-tuned the definition of end-organ damage, known as CRAB (hypercalcemia, renal insufficiency, anemia, and bone lesions). Considering Korea’s trend of aging at an unprecedented rate, we can expect that the ASR of MM will maintain a gradual increase for many years to come; therefore, MM will be a cancer of critical importance from both medical and socioeconomic perspectives in Korea.

show abstract

Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Cited by 45 publications

References 20 publications

Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia

Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea

Recent advances in multiple myeloma: a Korean perspective

Contact Info

Product

Resources

About